(Press Release) Milestone Achievement under License Agreement with Nippon Soda Co., Ltd.

MabGenesis and Nippon Soda today announced a milestone has been achieved related to the “Licensing of MabGenesis' Therapeutic Antibodies for Feline Inflammatory Diseases," which was previously disclosed in a press release on April 28, 2026.

Please see the joint press release here.